Tecovirimat-d4
Based on 1 Customer Validation
Tecovirimat-d4 (ST-246-d4) is a deuterium-labelled Tecovirimat (HY-14805). Tecovirimat is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat could be used in the study for orthopoxvirus-induced diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.95%
- CAS No.: 2923753-84-6
- Formule: C19H11D4F3N2O3
- Masse moléculaire:380.35
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 2923753-84-6
-
Unlabeled Cas 869572-92-9
-
Appearance Solid
-
Masse moléculaire 380.35
-
Formule C19H11D4F3N2O3
-
Color White to off-white
-
SMILES
O=C(NN(C([C@]1([H])[C@@]2([H])[C@@](C3)([H])[C@@]3([H])[C@@](C=C2)([H])[C@]41[H])=O)C4=O)C5=C([2H])C([2H])=C(C(F)(F)F)C([2H])=C5[2H]
-
Synonyms
ST-246-d4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (262.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yang G, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol. 2005 Oct;79(20):13139-49. [Content Brief]
[2]. Quenelle DC, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95. [Content Brief]
[3]. Andrew T Russo, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-344. [Content Brief]
[4]. DeLaurentis CE, et al. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus[J]. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0122622. [Content Brief]
[5]. Almehmadi M, et al. A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak[J]. Viruses. 2022 Aug 25;14(9):1870. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6292 mL | 13.1458 mL | 26.2916 mL | 65.7289 mL |
| 5 mM | 0.5258 mL | 2.6292 mL | 5.2583 mL | 13.1458 mL | |
| 10 mM | 0.2629 mL | 1.3146 mL | 2.6292 mL | 6.5729 mL | |
| 15 mM | 0.1753 mL | 0.8764 mL | 1.7528 mL | 4.3819 mL | |
| 20 mM | 0.1315 mL | 0.6573 mL | 1.3146 mL | 3.2864 mL | |
| 25 mM | 0.1052 mL | 0.5258 mL | 1.0517 mL | 2.6292 mL | |
| 30 mM | 0.0876 mL | 0.4382 mL | 0.8764 mL | 2.1910 mL | |
| 40 mM | 0.0657 mL | 0.3286 mL | 0.6573 mL | 1.6432 mL | |
| 50 mM | 0.0526 mL | 0.2629 mL | 0.5258 mL | 1.3146 mL | |
| 60 mM | 0.0438 mL | 0.2191 mL | 0.4382 mL | 1.0955 mL | |
| 80 mM | 0.0329 mL | 0.1643 mL | 0.3286 mL | 0.8216 mL | |
| 100 mM | 0.0263 mL | 0.1315 mL | 0.2629 mL | 0.6573 mL |
Powered by Bioz